Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
With
Eli Lilly and Company
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²)
Males who agree to follow contraceptive requirements and women of not childbearing potential
Have body weight greater than or equal to (\>=) 50 Kilograms at screening.
Must have a negative Interferon-Gamma Release Assays (IGRA) testing at screening
Must have been stopped all the prescribed medication at least 14 days prior to admission to the clinical site
Ability and willingness to abstain from alcohol, caffeine, and methylxanthine-containing beverages or food 2 days prior to admission to the clinical site
Abstain from any strenuous physical exercise from 4 days prior to admission and during confinement at the clinical site
You may not be if
Have a history of relevant drug and/or food allergies, or sensitivity to medications used in the current study
Females participants who are currently breastfeeding
Have History of alcohol abuse or drug addiction
Unable to abstain from tobacco products within the 2 days prior to admission and during confinement at the clinical site
Have Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) 1 and 2 antibodies
Consumption of any nutrients known to modulate CYP450 enzymes activity
Are immunocompromised
Have received live vaccine(s) (including attenuated live vaccines) or Bacillus Calmette-Guérin within 28 days of screening or intend to receive them during the study
Have had any malignancy within the past 5 years
Clareo Health | A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
